AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Assura PLC

Delisting Announcement Oct 28, 2024

4924_rns_2024-10-28_9f7547f7-808c-4c8e-875c-f5caa3371e1d.html

Delisting Announcement

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

RNS Number : 7696J

Assura PLC

28 October 2024

28 October 2024

Assura plc

Proposed secondary listing on the Johannesburg Stock Exchange

Assura plc ("Assura" or the "Company"), the UK's leading diversified healthcare REIT, is pleased to announce that it is in the process of applying for a secondary inward listing on the Main Board of the Johannesburg Stock Exchange (JSE) by way of an introduction.

Assura believes that admission to trading of the shares on the JSE will be beneficial to the Company and its stakeholders. The Board of Assura believes that the secondary listing can be expected to contribute to liquidity in the Company's shares through its increased profile in the South African market.

The listing of Assura on the JSE is expected to become effective later this year, subject to the necessary regulatory approvals in South Africa. The Company will not place or issue any new Assura shares in connection with its application for a secondary listing on the JSE and will remain listed on the Equity Shares (Commercial Companies) category (ESCC) of the Official List in London.

HSBC is acting as Listing Co-ordinator and Corporate Broker and Nedbank Corporate and Investment Banking, a division of Nedbank Limited, as JSE Sponsor.

Jonathan Murphy, CEO, said:

"We are excited to announce that we are moving forward with an application for a secondary listing on the Johannesburg Stock Exchange which we believe will contribute to liquidity in our shares.

"As the UK's leading diversified healthcare REIT, Assura offers an attractive proposition to South African investors, who we look forward to welcoming onto our share register. Our high quality assets offer long-term secured and growing income, underpinned by the long-term structural demand for healthcare services."

- Ends -

For more information, please contact:

Assura plc Tel:  0161 515 2043
David Purcell, Investor Relations Director Email:  [email protected]
FGS Global

Gordon Simpson

Grace Whelan
Tel:  0207 251 3801

Email:  [email protected]
HSBC Bank Plc

Chloe Ponsonby

Jonathan Surr

Louis Davies
Tel : 020 7991 8888

Notes to Editors

Assura plc is the UK's leading diversified healthcare REIT. Assura enables better health outcomes through its portfolio of more than 600 healthcare buildings, from which over six million patients are served.

A UK REIT based in Altrincham, Assura is a constituent of the FTSE 250 and the EPRA* indices. As at 31 March 2024, Assura's portfolio was valued at £2.7 billion and has a strong track record of growing financial returns and dividends for shareholders.

At Assura, we BUILD for health, having developed over 100 new healthcare buildings in our history, and at the heart of our strategy sits The Bigger Picture; Healthy Environment (E), Healthy Communities (S), Healthy Business (G).

Further information is available at   www.assuraplc.com

* EPRA is a registered trademark of the European Public Real Estate Association

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCGZMZGRNGGDZM

Talk to a Data Expert

Have a question? We'll get back to you promptly.